What VANTAVO (Dihydrotachysterol) Treats: Main Uses and Benefits

VANTAVO is commonly used to address clinical scenarios where systemic mineral regulation is affected, and helps maintain a sense of stability. The medication is commonly used in the management of hypocalcemia, hypophosphatemia, and associated bone disorders.

The primary therapeutic domain involves managing conditions related to parathyroid gland dysfunction (like Hypoparathyroidism). VANTAVO is relevant for easing symptoms of increased neurological or muscular activity, which may become intense or disruptive. This includes symptom clusters such as painful tetany, muscle cramps, and twitching, and it offers symptomatic relief when these manifestations interfere with routine activities. It plays a role in managing Metabolic Bone Diseases like Rickets and Osteomalacia, particularly in patients with impaired renal function and mineral deficits. In essence:

“The therapeutic benefit assists with maintaining functional stability and provides support during difficult episodes by easing distress.”

---

Quick Fact: Relief for Hypocalcemic Symptoms

Property	Description
Primary Therapeutic Goal	Support for Mineral Homeostasis (Calcium/Phosphate)
Key Indications	Hypoparathyroidism, Rickets, Osteomalacia
Symptom Relief Focus	Tetany, Muscle Cramps, Twitching
Patient Benefit	Contributes to improved comfort during symptomatic periods

The eligibility for using VANTAVO (Dihydrotachysterol) is strictly defined by regulatory documents, focusing on the patient's existing mineral status and certain underlying conditions.

Populations for Whom Use is Prohibited

The medicine is contraindicated and must not be used in patients with pre-existing hypercalcemia (abnormally high blood calcium levels), hypervitaminosis D (Vitamin D toxicity), or abnormal sensitivity to the effects of Vitamin D.

Restricted and Conditional Use

Category	Regulatory Eligibility Rule
Age-Related	Pediatric Use is approved (infants/children), but requires extreme care and individualized dosing due to the narrow therapeutic range.
Physiological State	Pregnancy: Classified as Category C; use is restricted to cases where the potential clinical benefit justifies the risk to the fetus.
Lactation: Use is contraindicated by some authorities, or requires caution, as Dihydrotachysterol may be excreted into breast milk.
Comorbidities	Patients with renal osteodystrophy and hyperphosphatemia must have their serum phosphorus level maintained at normal levels to ensure eligibility and prevent metastatic calcification.

Eligibility is primarily determined by ruling out pre-existing calcium excess and requiring careful monitoring in vulnerable groups.

Interactions with other medicines and products

This section addresses formally documented interaction patterns for VANTAVO (Dihydrotachysterol) as described in official government regulatory documents.

---

Contraindicated Combinations and Additive Effects

Co-administration with Calcium Supplements is strictly contraindicated due to the significantly enhanced, documented risk of developing hypercalcemia. Medicines that also raise calcium levels, such as Thiazide Diuretics, can increase the calcemic effect of Dihydrotachysterol; this additive interaction is specifically cautioned in patients with hypoparathyroidism. Furthermore, the risk of serious cardiac events, such as ventricular arrhythmias, is enhanced when VANTAVO-induced hypercalcemia occurs concurrently with the use of Cardiac Glycosides (e.g., Digoxin or Digitoxin).

---

Altered Exposure and Reduced Effectiveness

Several medicines may reduce the therapeutic effect of Dihydrotachysterol. This can occur through metabolic pathways, where drugs like anticonvulsants (e.g., Phenytoin) and anti-tuberculosis agents (e.g., Rifampicin, Isoniazid) are documented to accelerate the drug's breakdown. Alternatively, exposure is reduced when absorption is impaired by co-administered substances such as Bile Acid Sequestrants (e.g., Cholestyramine) or mineral oil. Thyroid replacement therapy may also increase the clearance of Dihydrotachysterol, leading to reduced systemic levels.

---

Non-Medicinal Product Interactions

Interaction-related constraints also extend to non-medicinal products. Dietary intake of calcium, phosphate, and vitamin D must be carefully adjusted to prevent toxic effects. Consumption of Grapefruit / Grapefruit Juice has also been noted in regulatory documents to alter the blood levels and subsequent effects of Dihydrotachysterol.

The core mechanism of Dihydrotachysterol is its action as an agonist at the nuclear Vitamin D Receptor (VDR). The active form of the drug binds to the VDR, creating a complex that moves into the cell nucleus and initiates the genomic transcription of specific genes. This action modulates key pathways associated with mineral regulation, resulting in the transcription and translation of proteins required for calcium transport.

This VDR-mediated mechanism simultaneously engages three major organ systems. It enhances calcium absorption from the intestines, boosts calcium reabsorption in the kidneys, and promotes controlled calcium mobilization (resorption) from the bone matrix. This systemic cascade results in a net positive balance of extracellular calcium concentration.

A unique mechanistic property of Dihydrotachysterol is its chemical structure, which requires only hepatic hydroxylation (in the liver) for activation, completely bypassing the subsequent rate-limiting activation step that normally occurs via the renal mathbf1-alpha-hydroxylase pathway.

Official Administration Instructions for VANTAVO

VANTAVO is an oral tablet administered once weekly. Strict adherence to the official procedural steps is necessary to ensure optimal absorption and minimize the risk of irritation to the esophagus, or gullet.

Administration Detail	Official Guideline
Dosing Schedule	One tablet once weekly, on a chosen day.
Timing (General)	Immediately after getting up for the day, and before the first intake of the day.
Timing (Food/Drink)	Must be taken at least 30 minutes before the first food, beverage, or medicinal product (including antacids, calcium, and vitamins) of the day.
Preparation	Swallow the tablet whole with a full glass of plain water (not mineral water, and not less than 200 ml or 7 fl. oz.). Do not crush, chew, or allow the tablet to dissolve in the mouth.

Special Procedural Steps

Following administration, the patient must remain fully upright (sitting, standing, or walking) for a minimum of 30 minutes, and remain upright until after consuming their first food of the day. This medicine must not be taken at bedtime or before arising. If a weekly dose is missed, the patient should take one tablet the morning after they remember. They must not take two tablets on the same day, but should then resume their original once-weekly schedule.

No dose adjustment is necessary for elderly patients. VANTAVO is not recommended for use in patients with severe renal impairment (Glomerular Filtration Rate < 35 ml/min) or in children under 18 years of age. Patients should receive supplemental calcium if their dietary intake is inadequate.

Recent Clinical Evidence: VANTAVO (Alendronic Acid/Colecalciferol)

The combination compound VANTAVO integrates alendronic acid (a bisphosphonate) with colecalciferol (Vitamin D3) and has been primarily investigated for the treatment of postmenopausal osteoporosis in women with a risk of Vitamin D deficiency.

---

Clinical Trial Findings

Bone Health Efficacy

Studies focused on the alendronic acid component indicate an association with a reduction in the risk of both vertebral and hip fractures in postmenopausal women with osteoporosis. This is consistent with the established mechanism of bisphosphonates, which targets the rate of bone breakdown.

Vitamin D Status

Research has explored the role of combining Vitamin D3 (colecalciferol) with alendronic acid in a single tablet. A key trial demonstrated that the administration of the combination was associated with a lower percentage of patients exhibiting low serum Vitamin D levels after a 15-week period, compared to patients receiving alendronic acid alone. Further extension studies explored different colecalciferol strengths and their relationship to increases in Vitamin D levels.

---

Safety Monitoring in Studies

Clinical trials followed defined protocols to monitor safety and tolerability across adult participants. Common adverse events observed in these studies included reports of mild gastrointestinal and musculoskeletal discomfort. Serious adverse events were reported infrequently across the trials.

Monitoring protocols addressed specific patient groups:

• Elderly Participants: Clinical studies found no age-related difference in the monitored safety profiles in the elderly population.
• Pediatric Use: The safety and effects of this combination therapy have not been established in patients under 18 years of age, and research data is not available for this population.
• Renal Function: Participants with severe renal impairment (low GFR) were generally excluded from trials or monitored closely, as data on use in this specific population is limited.

Common questions about VANTAVO (VITAMINS) (FAQ)

---

Q: What is the therapeutic goal or common use for VANTAVO?

According to official product information, VANTAVO is intended for use in managing and regulating calcium and phosphate levels in the body. It is often prescribed for conditions associated with abnormally low blood calcium, such as hypoparathyroidism. The medication helps address mineral imbalances in patients with certain kidney-related bone conditions, such as renal osteodystrophy.

---

Q: How long will I have to take VANTAVO?

Treatment with medicines of this type is typically long-term, especially when managing chronic conditions like hypoparathyroidism. The duration of therapy is a decision made by a healthcare provider based on continuous monitoring of the patient’s blood calcium levels. This ensures the treatment remains appropriate and balanced over time.

---

Q: Can I crush my VANTAVO tablet if I have trouble swallowing?

Official administration instructions specify that the VANTAVO tablet must be swallowed whole and must not be crushed, chewed, or allowed to dissolve in the mouth. This procedure helps to ensure optimal absorption of the medicine. It also minimizes the risk of irritation to the esophagus, or gullet, as outlined in regulatory guidelines.

---

Q: What is the recommended dose for children taking VANTAVO?

Official labeling states that Dihydrotachysterol (VANTAVO) is approved for use in infants and children. However, a healthcare provider individualizes the dose, meaning it is specifically adjusted for each child. The initial and maintenance doses are set based on regular monitoring of the child’s calcium levels to achieve the correct therapeutic balance.

---

Q: What should I do if I miss my weekly VANTAVO tablet dose?

The official instruction for a missed dose is to take one tablet the morning after the missed day is remembered. It is specifically noted in the regulatory documents that two tablets must not be taken on the same day. After taking the missed dose, the patient should then resume their original once-weekly schedule.

---

Q: Can I drink coffee or tea when taking my VANTAVO in the morning?

VANTAVO must be taken with a full glass of plain water immediately upon rising, before consuming anything else. The medicine requires a minimum waiting period of 30 minutes before consuming any food, beverage, or medicinal product, and this includes both coffee and tea.

---

Q: Can I take an antacid or a calcium supplement at the same time as VANTAVO?

Official instructions specify a timing constraint: the medicine must be taken at least 30 minutes before any other product, including antacids and calcium or vitamin supplements. The co-administration of calcium supplements is strictly discouraged by regulatory documents due to the high risk of developing hypercalcemia (excessive calcium in the blood).

---

Q: How do I safely throw away any leftover VANTAVO?

Unused or expired VANTAVO should not be flushed down the toilet or poured into any drain. The official protocol prioritizes the use of an authorized drug take-back program for disposal. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container for disposal with household trash.

---

Q: I'm pregnant/breastfeeding. Is it safe for me to use VANTAVO?

In regulatory documents, VANTAVO is classified as Pregnancy Category C. This means its use is generally limited to cases where the potential clinical benefit is judged to justify the potential risk to the fetus. Use during lactation is generally contraindicated, or requires extreme caution, as the drug may be excreted into breast milk.

---

How to Store and Dispose of VANTAVO (Dihydrotachysterol)

Official regulatory labeling dictates specific conditions for storing and discarding VANTAVO to ensure chemical stability and safety.

Storage Conditions

VANTAVO must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product requires mandatory protection from both light and moisture and must be kept in its original, tightly closed container; it must not be frozen or exposed to excessive heat. Due to the risk of accidental ingestion, VANTAVO must be kept out of the sight and reach of children and stored in a secure location.

Disposal Instructions

Unused or expired VANTAVO should not be flushed down the toilet or poured into any drain. Disposal must follow a structured protocol, prioritizing the use of an authorized drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed container before disposal with household trash.